Inactivation of Cancer Mutations Utilizing CRISPR/Cas9
Christina Gebler1, Tim Lohoff1, Maciej Paszkowski-Rogacz1
1Affiliations of author: Medical Systems Biology, Medical Faculty Carl Gustav Carus, University cancer center, Technische Universitat Dresden, Dresden, Germany.
Abstract:
Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.
More Related Videos
Related Concept Videos
CRISPR
CRISPR
CRISPR/Cas9 Genome Editing
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
In-vitro Mutagenesis
Homologous Recombination


